Abstract
Cloning of the insulin-like growth factor I (IGF-I) gene led to the development in 1987 of recombinant IGF-I available for clinical use. Trials were started targeting endocrine, metabolic and neurological disorders, and beneficial results have been demonstrated in IGF-I deficiency states caused by IGF-I gene deletion and growth hormone (GH) receptor deficiency, type 1 and type 2 diabetes mellitus, and severe insulin resistance syndromes. Results of equivocal benefit have also been reported in osteoporosis and amyotrophic lateral sclerosis. Recent encouraging data using the IGF-I-IGF-binding protein 3 (IGFBP-3) complex in diabetes mellitus suggest that this preparation may eventually replace recombinant free IGF-I. The lack of an established therapeutic indication for IGF-I has resulted in its supplies being severely limited. It will probably be decided during the next decade whether use of IGF-I or the IGF-I-IGFBP-3 complex becomes firmly established as an accepted endocrine therapy.
Original language | English (US) |
---|---|
Pages (from-to) | S65-S69 |
Journal | Growth Hormone and IGF Research |
Volume | 11 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - 2001 |
Keywords
- Amyotrophic lateral sclerosis
- Diabetes mellitus
- Growth hormone receptor deficiency
- Insulin resistance
- Insulin-like growth factor I
- Osteoporosis
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology